Peter Smith
Director/Miembro de la Junta en RYVU THERAPEUTICS S.A. .
Cargos activos de Peter Smith
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| RYVU THERAPEUTICS S.A. | Director/Miembro de la Junta | 14/06/2023 | - |
Remix Therapeutics, Inc.
 Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Director Ejecutivo | 17/08/2021 | - |
| Fundador | - | - | |
| Presidente | - | - | |
| Director Técnico/Científico/I+D | - | 17/08/2021 | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultor / Asesor | 01/01/2018 | - |
Amplify Medicines, Inc.
 Amplify Medicines, Inc. Pharmaceuticals: GenericHealth Technology Part of Ikena Oncology, Inc., Amplify Medicines, Inc. develops pharmaceutical drugs. The company is based in Boston, MA. The company was founded by Peter Smith. | Director Técnico/Científico/I+D | - | - |
| Fundador | - | - |
Historial de carrera de Peter Smith
Antiguos cargos conocidos de Peter Smith.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | 01/01/2011 | 31/12/2018 |
Formación de Peter Smith.
| Newcastle University | Doctorate Degree |
| University of Sheffield Medical School | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 5 |
| Reino Unido | 3 |
| Polonia | 2 |
Operativa
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
| Chief Executive Officer | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| RYVU THERAPEUTICS S.A. | Health Technology |
| Empresas privadas | 4 |
|---|---|
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Amplify Medicines, Inc.
Amplify Medicines, Inc. Pharmaceuticals: GenericHealth Technology Part of Ikena Oncology, Inc., Amplify Medicines, Inc. develops pharmaceutical drugs. The company is based in Boston, MA. The company was founded by Peter Smith. | Health Technology |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Bolsa de valores
- Insiders
- Peter Smith
- Experiencia
